Craig Coleman from the University of Connecticut School of Pharmacy: Novel Oral Anticoagulants Show Positive Results in Real World Setting
For many years, warfarin has been the primary option for anticoagulation, but recently newer medications have been approved that may provide better options for this patient population. While the clinical trials of the novel oral anticoagulant drugs showed positive results, there were still lingering questions about how they would fare in the field.
For many years, warfarin has been the primary option for anticoagulation, but recently newer medications have been approved that may provide better options for this patient population. While the clinical trials of the novel oral anticoagulant drugs showed positive results, there were still lingering questions about how they would fare in the field.
Prior to speaking at the European Cardia Arrhythmia Society's annual congress in Paris, France, Craig Coleman, PharmD, from the University of Connecticut College of Medicine, discussed the results of the REVISIT-US Study with MD Magazine at the American College of Cardiology's annual meeting in Chicago.
The REVISIT-US Study looked at the effect on occurrence of ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation treated with rivaroxaban, apixaban, or warfarin.
Coleman said that while the noval oral anticoagulants may not have the history of warfarin, the study showed that they provide alternatives for physicians looking to find better treatment options for their patients.
